Clinical Trial Update: Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells [Phase 2]

View source ↗

Summary

Phase 2 study investigating fecal microbiota transplant to remodel gut microbiota in patients with relapsed/refractory diffuse large B-cell lymphoma receiving C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements

Drugs mentioned

• Chimeric Antigen Receptor T-cell Therapy (CAR-T cell therapy)
• Fecal microbiota transplant (fecal microbiota transplant)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Phase 2 | Status: RECRUITING